FUTURTEC

FUTURTEC ranks among China’s pioneering orthopedic surgical robot companies, developing intelligent spine surgery systems that combine navigation with autonomous execution capabilities. The company achieved a significant milestone in February 2021 when its ORTHBOT system became one of the first orthopedic robots in China to receive NMPA approval with active needle placement functionality.

Company Overview

Established in 2015 in Shenzhen as a national high-tech enterprise, FUTURTEC focuses on creating intelligent orthopedic surgical robot platforms that integrate robotics with artificial intelligence. The company maintains R&D centers in both Shenzhen and Suzhou, staffed by an international team with expertise spanning orthopedic surgical robotics, medical imaging, and AI.

FUTURTEC’s founding vision centered on addressing key limitations in traditional spine surgery—specifically the challenges surgeons face in visualizing deep structures and translating preoperative plans into precise intraoperative execution. The company’s approach combines navigation technology with robotic execution, moving beyond simple positioning aids toward systems capable of performing surgical tasks.

Core Products

ORTHBOT Spine Surgical Robot

ORTHBOT represents FUTURTEC’s flagship product, which the company describes as China’s first orthopedic surgical robot with active needle placement capabilities. Unlike navigation-only systems that merely guide surgeons to target locations, ORTHBOT executes the planned surgical pathway under physician supervision.

The system provides intervention planning on 2D X-ray images from C-arms, intraoperative navigation, and robotic positioning for K-wire insertion in pedicle procedures. ORTHBOT employs a proprietary non-invasive optical tracking solution embedded in the robotic arm, eliminating the need for implanted fiducial markers that other systems require.

Key clinical applications include percutaneous kyphoplasty (PKP) for spine fractures and pedicle screw placement across the full spine from cervical to sacral vertebrae.

Development Pipeline

FUTURTEC continues expanding its orthopedic platform with osteotomy modules and joint replacement surgical robots currently under development. These pipeline products aim to extend the company’s technology into additional high-volume orthopedic procedures.

Technology & Innovation

FUTURTEC has accumulated substantial intellectual property, with over 126 patents filed domestically and internationally. The patent portfolio includes authorized patents in the United States and multiple PCT international applications.

The company’s technical differentiation centers on three core capabilities:

Non-invasive Tracking: ORTHBOT’s optical tracking system attaches to the robotic arm rather than requiring pins or markers implanted in the patient, reducing procedural complexity and potential complications.

Pressure Feedback Monitoring: Real-time force sensing during instrument insertion provides surgeons with tactile information about bone density and positioning accuracy.

Autonomous Execution: The system moves beyond navigation to actually perform planned movements, with the surgeon supervising rather than manually executing each step.

Market Presence

FUTURTEC established its first clinical application research base at Nanfang Hospital (Southern Medical University) in January 2022. The company has presented ORTHBOT at major orthopedic conferences including the Chinese Orthopedic Association (COA) annual congress.

In May 2023, FUTURTEC became the first and only Chinese company to obtain MDR CE certification in the orthopedic robot field, opening European market access. This positions the company for international expansion beyond its domestic base.

Key Milestones

• 2015: Company founded in Shenzhen
• 2021-02: ORTHBOT receives NMPA approval as China’s first spine robot with active needle placement
• 2021-10: Completes Series B financing led by SoftBank Vision Fund 2, Huatai Zijin, and Sinovation Ventures
• 2022-01: Establishes first clinical research base at Nanfang Hospital
• 2022-04: Named “Best Innovative Medical Device Company of 2021” by Haoyu Capital
• 2023-05: Obtains MDR CE certification, first Chinese orthopedic robot company to achieve this

Frequently Asked Questions

What makes ORTHBOT different from other spine surgery robots?

ORTHBOT combines navigation with autonomous execution—the robot physically places K-wires rather than just showing surgeons where to place them. It also uses non-invasive optical tracking that doesn’t require pins or markers implanted in the patient.

Is FUTURTEC publicly traded?

No, FUTURTEC remains a privately held company. The company completed a Series B financing round in October 2021 with participation from SoftBank Vision Fund 2, Huatai Zijin Investment, Sinovation Ventures, ABCI Securities, and existing investor Morningside Ventures.

What regulatory approvals does ORTHBOT have?

ORTHBOT received NMPA (China) approval in February 2021 and MDR CE (European Union) certification in May 2023. The system does not currently have FDA clearance for the U.S. market.

What procedures can ORTHBOT perform?

ORTHBOT supports spine procedures including percutaneous kyphoplasty (PKP) for vertebral compression fractures and pedicle screw placement. The system covers the full spine from cervical to sacral regions.